BioLargo (NASDAQ:BLGO – Get Free Report) is one of 34 public companies in the “Chemicals & allied products” industry, but how does it compare to its peers? We will compare BioLargo to similar businesses based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, institutional ownership and dividends.
Profitability
This table compares BioLargo and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
BioLargo | -16.53% | -58.35% | -32.12% |
BioLargo Competitors | -568.74% | 5.73% | -0.15% |
Valuation & Earnings
This table compares BioLargo and its peers top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
BioLargo | $12.23 million | -$3.50 million | -7.89 |
BioLargo Competitors | $6.63 billion | $206.77 million | 66.08 |
Institutional & Insider Ownership
0.0% of BioLargo shares are owned by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are owned by institutional investors. 20.3% of BioLargo shares are owned by company insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
BioLargo has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s peers have a beta of 1.78, indicating that their average share price is 78% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and price targets for BioLargo and its peers, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
BioLargo | 0 | 0 | 0 | 0 | N/A |
BioLargo Competitors | 139 | 1276 | 1591 | 46 | 2.51 |
As a group, “Chemicals & allied products” companies have a potential upside of 6.35%. Given BioLargo’s peers higher possible upside, analysts plainly believe BioLargo has less favorable growth aspects than its peers.
Summary
BioLargo peers beat BioLargo on 8 of the 10 factors compared.
About BioLargo
BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.